Does Enclomiphene Work? What the Evidence Shows

Does enclomiphene work? In the studies done so far, enclomiphene and its parent compound clomiphene do appear to raise testosterone in men with functional or secondary hypogonadism — and they tend to do so while preserving fertility, unlike standard testosterone replacement. A 2025 systematic review and meta-analysis of 10 randomized controlled trials (819 men) reported a pooled increase in total testosterone of about +274 ng/dL versus placebo. That is a meaningful signal, but it comes from short-term trials, the evidence base is underpowered for safety, and enclomiphene is not FDA-approved. This article is educational information, not medical advice.

What is enclomiphene and how is it supposed to work?

Enclomiphene is the trans-isomer (the anti-estrogenic stereoisomer) of clomiphene, a selective estrogen receptor modulator, or SERM. According to a 2026 British Society of Sexual Medicine position statement, it works by blocking estrogen receptors in the pituitary, which prompts the body to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Those hormones, in turn, signal the testes to produce more of the body’s own testosterone and to keep making sperm.

That mechanism is the key contrast with testosterone replacement therapy (TRT). Exogenous testosterone suppresses the brain’s signaling to the testes and can impair sperm production; enclomiphene aims to stimulate the body’s own production instead. In other words, the goal is to restore the body’s own testosterone production rather than replace it. If you want the foundational primer, see what is enclomiphene, and for the side-by-side, see enclomiphene vs TRT.

What does the strongest evidence actually show?

The most comprehensive picture comes from the 2025 meta-analysis published in Archives of Endocrinology and Metabolism. It pooled 10 RCTs and 819 participants (374 on a SERM, 205 on placebo, 133 on testosterone gel, 94 on hCG, 13 on anastrozole), with follow-up ranging from 2 to 30 weeks, in men with functional or secondary hypogonadism. Here is what it found, with the figures attached to their exact comparisons.

Outcome (SERM vs comparator)	Pooled result	95% CI	Notes
Total testosterone vs placebo	+273.76 ng/dL	191.87 to 355.66	p<0.01; high heterogeneity (I²=89%)
LH vs placebo	+4.66 IU/L	3.37 to 5.94	p<0.01; I²=55%
FSH vs placebo	+4.59 IU/L	2.88 to 6.30	p<0.01; I²=68%
Total testosterone vs testosterone gel	+5.41 ng/dL	-43.44 to 54.27	p=0.83 (no significant difference); I²=0%
Sperm concentration vs testosterone gel	+70.40 million/mL	41.62 to 99.18	p<0.01; favors SERM
Risk of sperm concentration <15 million/mL vs gel	RR 0.10	0.04 to 0.23	p<0.01; markedly lower risk with SERM

Two things stand out. First, on testosterone itself, SERMs were statistically comparable to testosterone gel — the difference of +5.41 ng/dL was not significant (p=0.83). So the evidence does not say SERMs raise testosterone more than gel; it suggests they raise it to a broadly similar degree. Second, the fertility contrast is where SERMs separate from gel: sperm concentration was about +70 million/mL higher with SERMs, and the risk of dropping below the 15 million/mL threshold was about 90% lower (RR 0.10). All of these are findings in defined trial populations, not guaranteed outcomes — individual results vary and are provider-determined.

How does this compare with the original enclomiphene trials?

The meta-analysis pooled clomiphene and enclomiphene together as SERMs. For enclomiphene specifically, the landmark data come from a 2014 phase II randomized controlled trial (Wiehle et al., Fertility and Sterility) in men with secondary hypogonadism. In that study, oral enclomiphene citrate increased morning serum testosterone, estradiol, and LH similar to topical testosterone gel, while raising FSH and LH and conserving sperm counts. The authors concluded that enclomiphene “reverses the two hallmarks of secondary hypogonadism… while preserving sperm production.” That early signal is consistent with the broader 2025 pooled analysis.

If you are weighing the underlying compound, enclomiphene vs clomiphene explains the isomer distinction in more depth, and enclomiphene side effects covers tolerability considerations.

What are the limits of this evidence?

This is the part that matters most for an honest answer. The 2025 meta-analysis is, by its authors’ own description, the largest pooled analysis to date — but they caution that it “remains underpowered with regard to safety endpoints” and is limited by high between-study heterogeneity (I²=89% for the testosterone result). In plain terms: the trials varied a lot, were short (2 to 30 weeks), and weren’t large enough to draw firm safety conclusions.

The British Society of Sexual Medicine reaches a similar verdict, describing the enclomiphene evidence as “small, short-term studies with limited safety and fertility data” and noting that long-term efficacy and safety data are lacking, while recommending that use be limited to specialist or research settings. So while the testosterone-raising signal is fairly consistent, durable efficacy and long-term safety are not yet established. Dosing in the trials was specific (for example, 12.5 mg and 25 mg enclomiphene in the Wiehle study), but dosing is provider-determined and not a Revive protocol; see enclomiphene dosage for context.

What is the regulatory status of enclomiphene?

Enclomiphene is not approved by the FDA (or the European Medicines Agency). It is available only through compounding pharmacies and is used off-label in men. It sits in FDA 503A Category 1 (Under Evaluation) on the bulk drug substances list, which was updated May 14, 2026. In a related step, on June 8, 2022 the FDA Pharmacy Compounding Advisory Committee voted against adding enclomiphene citrate to the final 503A Bulks List, with members citing a lack of clinical efficacy evidence.

One important precision point: clomiphene citrate is FDA-approved for female infertility (for example, Clomid), but its use in men — and pure enclomiphene for men — is off-label or unapproved. Enclomiphene does not inherit any FDA approval from clomiphene.

How does enclomiphene compare with TRT?

Testosterone replacement is a different regulatory and clinical category. Testosterone is a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990 and requires a valid prescription. Diagnosis follows the American Urological Association guideline, which recommends a total testosterone below 300 ng/dL on at least two early-morning measurements, combined with relevant symptoms. TRT also requires ongoing monitoring (such as hemoglobin/hematocrit, PSA, and blood pressure).

On safety labeling, on February 28, 2025 the FDA required class-wide changes to all testosterone products: it removed the boxed warning about cardiovascular risk and added a new warning about an increase in blood pressure, informed by the TRAVERSE trial (Lincoff et al., NEJM 2023) — 5,246 hypogonadal men aged 45 to 80, with major adverse cardiac events of 7.0% on testosterone vs 7.3% on placebo over a mean follow-up of about 33 months (mean treatment duration about 22 months). Those TRAVERSE figures and the blood-pressure warning belong to FDA-approved testosterone products — not to enclomiphene — and are included here only for the TRT comparison.

	Enclomiphene (compounded)	Testosterone (TRT)
Mechanism	SERM; stimulates the body’s own production	Replaces testosterone directly
Effect on sperm	Tends to preserve sperm (per trials)	Can suppress sperm production
Regulatory status	Not FDA-approved; compounded; off-label in men	FDA-approved products exist; Schedule III controlled substance
Diagnosis/monitoring	Provider-determined; off-label	Requires diagnosis (two low AM tests + symptoms) and monitoring

For deeper reading on the TRT side, see is testosterone a controlled substance and how long does TRT take to work.

So — does enclomiphene work?

Based on current evidence, enclomiphene (and clomiphene) appears to raise testosterone, LH, and FSH in men with functional or secondary hypogonadism, with effects on testosterone comparable to testosterone gel and a notable advantage in preserving sperm production. But “works” has limits: the trials are short, the pooled analysis is underpowered for safety, long-term data are lacking, and the product is not FDA-approved. Whether it is appropriate for any individual is a clinical decision that depends on labs, symptoms, fertility goals, and a licensed provider’s judgment.

Frequently asked questions

Does enclomiphene raise testosterone?

In a 2025 meta-analysis of 10 RCTs (819 men with functional or secondary hypogonadism), SERM therapy — clomiphene or enclomiphene — raised total testosterone by a pooled mean difference of about +274 ng/dL versus placebo (95% CI 191.87 to 355.66; p<0.01). This is a study finding in a defined population, not a guaranteed result; individual results vary and are provider-determined.

Is enclomiphene as effective as TRT?

For raising testosterone, the same meta-analysis found no statistically significant difference between SERMs and testosterone gel (mean difference +5.41 ng/dL; p=0.83), suggesting comparable testosterone-raising effects. The main difference is fertility: SERMs preserved sperm production far better than gel (sperm concentration +70.40 million/mL). The evidence is short-term, however, and enclomiphene is not FDA-approved.

Does enclomiphene preserve fertility?

In trials, SERMs preserved sperm production much better than testosterone gel, which can suppress it. Versus gel, sperm concentration was higher with SERMs and the risk of falling below 15 million/mL was markedly lower (RR 0.10). This contrasts with standard testosterone replacement, which can impair spermatogenesis. Fertility outcomes are individual and should be discussed with a provider.

Is enclomiphene FDA-approved?

No. Enclomiphene is not approved by the FDA (or the EMA). It is compounded, used off-label in men, and is on the FDA 503A Category 1 (Under Evaluation) list (list updated May 14, 2026). In 2022, an FDA advisory committee voted against adding it to the 503A Bulks List. The FDA has not evaluated compounded enclomiphene for safety, quality, or efficacy.

How long does enclomiphene take to work?

The published trials were short, with follow-up ranging from 2 to 30 weeks in the 2025 meta-analysis, and hormonal changes (LH, FSH, testosterone) were measured within those windows. There is no established timeline for individual results, and long-term efficacy data are limited. Any expected timeframe should be determined by a licensed provider based on labs and symptoms.

Is the evidence for enclomiphene strong?

It is mixed. The 2025 meta-analysis is the largest pooled analysis to date and shows a consistent testosterone-raising signal, but its authors say it “remains underpowered with regard to safety endpoints” and note high heterogeneity. The British Society of Sexual Medicine describes the evidence as small, short-term studies lacking long-term safety data. The signal is promising but not definitive.